SEC Comment Letter 0000000000-23-005361 to Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp.
Date: May 19, 2023 · CIK: 0001841330 · Accession: 0000000000-23-005361
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271896
Letter
United States securities and exchange commission logo May 19, 2023 Tiago Reis Marques, M.D., Ph.D. Chief Executive Officer Pasithea Therapeutics Corp. 1111 Lincoln Road, Suite 500 Miami Beach, FL 33139 Re:Pasithea Therapeutics Corp. Registration Statement on Form S-3 Filed May 12, 2023 File No. 333-271896 Dear Tiago Reis Marques: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James O’Grady, Esq.
Show Raw Text
United States securities and exchange commission logo
May 19, 2023
Tiago Reis Marques, M.D., Ph.D.
Chief Executive Officer
Pasithea Therapeutics Corp.
1111 Lincoln Road, Suite 500
Miami Beach, FL 33139
Re:Pasithea Therapeutics Corp.
Registration Statement on Form S-3
Filed May 12, 2023
File No. 333-271896
Dear Tiago Reis Marques:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: James O’Grady, Esq.